Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 8/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 4/20 | 0.60 |
| ▸ | KDR | P35968 | 5/20 | 0.53 |
| ▸ | MAP3K8 | P41279 | 6/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.52 |
| ▸ | CLK2 | P49760 | 3/20 | 0.52 |
| ▸ | CLK3 | P49761 | 3/20 | 0.52 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 3/20 | 0.49 |
| ▸ | WNT1 | P04628 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5517513 | 0.94 | CDK1 (0.66) | CDK1ERBB2KDRMAP3K8DYRK1A | |
| SCHEMBL14493339 | 0.89 | CDK1 (0.53) | CDK1ERBB2KDRMAP3K8DYRK1A | |
| SCHEMBL5511805 | 0.86 | CDK1 (0.57) | CDK1ERBB2KDRMAP3K8DYRK1A | |
| SCHEMBL5519983 | 0.86 | CDK1 (0.57) | CDK1ERBB2KDRMAP3K8DYRK1A | |
| SCHEMBL5508952 | 0.86 | CDK1 (0.51) | CDK1ERBB2KDRMAP3K8DYRK1A | |
| SCHEMBL21577729 | 0.86 | CDK1 (0.48) | CDK1ERBB2KDRMAP3K8DYRK1A | |
| SCHEMBL5512120 | 0.85 | CDK1 (0.70) | CDK1ERBB2KDRMAP3K8DYRK1A | |
| SCHEMBL5518822 | 0.85 | MAP3K8 (0.65) | CDK1KDRMAP3K8DYRK1ACLK2 | |
| SCHEMBL5516461 | 0.84 | CDK1 (0.70) | CDK1ERBB2KDRMAP3K8DYRK1A | |
| SCHEMBL5517983 | 0.84 | CDK1 (0.57) | CDK1ERBB2KDRMAP3K8DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183929-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180162840-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-06-14 | — | — | US | disclosed |
| US-20180162840-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-06-14 | — | — | US | disclosed |
| US-9908867-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-03-06 | — | — | US | disclosed |
| US-9908867-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-03-06 | — | — | US | disclosed |
| WO-2014110086-A2 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2014-07-17 | — | — | WO | disclosed |
| US-20140194441-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-20140194441-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2014-07-10 | — | — | US | disclosed |
| US-7232912-B2 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232912-B2 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-20060111322-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. | 2006-05-25 | — | — | US | disclosed |
| US-20050239855-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-6919461-B2 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030139463-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | REICH SIEGFRIED HEINZ (US) | 2003-07-24 | — | — | US | disclosed |
| US-6555539-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS | 2003-04-29 | — | — | US | disclosed |
| US-20020161022-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS | 2002-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239855-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | CDK1 9/4885ERBB2 391/4885KDR 69/4885 |
| US-20020161022-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | CDK1 9/4885ERBB2 391/4885KDR 69/4885 |
| US-20030139463-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, MKI67, ROCK1 | CDK1 9/4885ERBB2 391/4885KDR 69/4885 |
| US-10183929-B2 | 3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | CDK1 113/4885ERBB2 381/4885KDR 80/4885 |
| US-20140194441-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CDK1 113/4885ERBB2 381/4885KDR 80/4885 |
| US-20180162840-A1 | 3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | CDK1 113/4885ERBB2 381/4885KDR 80/4885 |
| US-20060111322-A1 | Indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | MKI67, CCNI, CDK3 | CDK1 11/4885ERBB2 675/4885KDR 2432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.